Abstract
mTOR is a key regulator of cell growth and size, and its activity is often dysregulated in a wide variety of diseases. The mTOR signaling pathway is also a therapeutic target for many diseases, including cancer. Immunohistochemistry is a powerful method to assess mTOR activity in clinical/histological samples, however, care should be taken in choosing the targets for determining mTOR activity due to the complexity of its regulation. This chapter describes the most up-to-date methods for visualizing mTOR activity by immunohistochemistry using commercially available antibodies, including considerations for validating new antibodies for assessing mTOR signaling.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Evren, S., Dermen, A., Lockwood, G., Fleshner, N., and Sweet, J. 2010 Immunohistochemical examination of the mTORC1 pathway in high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinomas (PCa): a tissue microarray study (TMA), Prostate 70, 1429–1436.
Clark, C., Shah, S., Herman-Ferdinandez, L., Ekshyyan, O., Abreo, F., Rong, X., McLarty, J., Lurie, A., Milligan, E. J., and Nathan, C. O. 2010 Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients, Laryngoscope 120, 1159–1165.
Hirashima, K., Baba, Y., Watanabe, M., Karashima, R., Sato, N., Imamura, Y., Hiyoshi, Y., Nagai, Y., Hayashi, N., Iyama, K., and Baba, H. 2010 Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma, Ann Surg Oncol 17, 2486–2493.
Andersen, J. N., Sathyanarayanan, S., Di Bacco, A., Chi, A., Zhang, T., Chen, A. H., Dolinski, B., Kraus, M., Roberts, B., Arthur, W., Klinghoffer, R. A., Gargano, D., Li, L., Feldman, I., Lynch, B., Rush, J., Hendrickson, R. C., Blume-Jensen, P., and Paweletz, C. P. 2010 Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors, Sci Transl Med 2, 43 ra55.
Kim, J., Jonasch, E., Alexander, A., Short, J. D., Cai, S., Wen, S., Tsavachidou, D., Tamboli, P., Czerniak, B. A., Do, K. A., Wu, K. J., Marlow, L. A., Wood, C. G., Copland, J. A., and Walker, C. L. (2009) Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma, Clin Cancer Res 15, 81–90.
Baba, Y., Nosho, K., Shima, K., Meyerhardt, J. A., Chan, A. T., Engelman, J. A., Cantley, L. C., Loda, M., Giovannucci, E., Fuchs, C. S., and Ogino, S. 2010 Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer, Br J Cancer 103, 1025–1033.
Werner, M., Chott, A., Fabiano, A., and Battifora, H. (2000) Effect of formalin tissue fixation and processing on immunohistochemistry, Am J Surg Pathol 24, 1016–1019.
Onda, H., Lueck, A., Marks, P. W., Warren, H. B., and Kwiatkowski, D. J. (1999) Tsc2(+/−) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background, J Clin Invest 104, 687–695.
Kwiatkowski, D. J., Zhang, H., Bandura, J. L., Heiberger, K. M., Glogauer, M., el-Hashemite, N., and Onda, H. (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells, Hum Mol Genet 11, 525–534.
Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C. L., Vera, D. R., and Shaw, R. J. (2009) mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome, Proc Natl Acad Sci USA 106, 11137–11142.
Blando, J., Portis, M., Benavides, F., Alexander, A., Mills, G., Dave, B., Conti, C. J., Kim, J., and Walker, C. L. (2009) PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth, Am J Pathol 174, 1869–1879.
Yeung, R. S., Xiao, G. H., Everitt, J. I., Jin, F., and Walker, C. L. (1995) Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumors in the Eker rat, Mol Carcinog 14, 28–36.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kim, J., Otto, N., Conti, C.J., Gimenz-Conti, I.B., Walker, C.L. (2012). Immunohistochemical Analysis of mTOR Activity in Tissues. In: Weichhart, T. (eds) mTOR. Methods in Molecular Biology, vol 821. Humana Press. https://doi.org/10.1007/978-1-61779-430-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-61779-430-8_12
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-429-2
Online ISBN: 978-1-61779-430-8
eBook Packages: Springer Protocols